AU2016248443B2 - Fasting mimicking diet (FMD) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone - Google Patents

Fasting mimicking diet (FMD) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone Download PDF

Info

Publication number
AU2016248443B2
AU2016248443B2 AU2016248443A AU2016248443A AU2016248443B2 AU 2016248443 B2 AU2016248443 B2 AU 2016248443B2 AU 2016248443 A AU2016248443 A AU 2016248443A AU 2016248443 A AU2016248443 A AU 2016248443A AU 2016248443 B2 AU2016248443 B2 AU 2016248443B2
Authority
AU
Australia
Prior art keywords
conditions
fmd
rapamycin
dexamethasone
standard
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016248443A
Other languages
English (en)
Other versions
AU2016248443A1 (en
Inventor
Stefano DI BIASE
Valter D. Longo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California
Original Assignee
University of Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California filed Critical University of Southern California
Publication of AU2016248443A1 publication Critical patent/AU2016248443A1/en
Application granted granted Critical
Publication of AU2016248443B2 publication Critical patent/AU2016248443B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016248443A 2015-04-16 2016-04-18 Fasting mimicking diet (FMD) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone Active AU2016248443B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562148451P 2015-04-16 2015-04-16
US62/148,451 2015-04-16
PCT/US2016/028055 WO2016168802A2 (en) 2015-04-16 2016-04-18 Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone

Publications (2)

Publication Number Publication Date
AU2016248443A1 AU2016248443A1 (en) 2017-11-02
AU2016248443B2 true AU2016248443B2 (en) 2021-03-18

Family

ID=57126369

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016248443A Active AU2016248443B2 (en) 2015-04-16 2016-04-18 Fasting mimicking diet (FMD) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone

Country Status (14)

Country Link
US (2) US20160303056A1 (cg-RX-API-DMAC10.html)
EP (2) EP4299061A3 (cg-RX-API-DMAC10.html)
JP (2) JP2018511625A (cg-RX-API-DMAC10.html)
KR (1) KR20180002677A (cg-RX-API-DMAC10.html)
CN (1) CN107613979A (cg-RX-API-DMAC10.html)
AU (1) AU2016248443B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017022244A2 (cg-RX-API-DMAC10.html)
CA (2) CA3108664A1 (cg-RX-API-DMAC10.html)
HK (1) HK1249858A1 (cg-RX-API-DMAC10.html)
IL (1) IL255026A0 (cg-RX-API-DMAC10.html)
MX (1) MX2017013133A (cg-RX-API-DMAC10.html)
RU (1) RU2734774C2 (cg-RX-API-DMAC10.html)
WO (1) WO2016168802A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201707710B (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3291693A4 (en) * 2015-05-06 2019-04-03 University of Southern California FASTENIMITIER AND IMPROVING DIET FOR THE TREATMENT OF HYPERTENSION AND LIPID DISORDER
JP2019505592A (ja) 2016-02-15 2019-02-28 ユニバーシティ オブ サザン カリフォルニア 糖尿病及び他の疾患を治療するための胚様再生を刺激するための薬剤の組み合わせ及び方法
KR20180136551A (ko) 2016-05-11 2018-12-24 유니버시티 오브 써던 캘리포니아 위장 자가면역/염증 질환을 위한 면역조절 치료로서의 단식 모방 식이(fmd)
WO2018102393A1 (en) * 2016-11-30 2018-06-07 Cure Cancer Worldwide Llc System for chemotherapy delivery and method of the same
US11284640B2 (en) * 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
MX2020009613A (es) 2018-03-15 2021-02-26 Univ Southern California Dieta que imita el ayuno (fmd) pero no ayuno solo con agua, promueve la reversion de la inflamacion y patologia de la enfermedad de intestino irritable (ibd).
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University COMBINATION THERAPY FOR A PI3K-ASSOCIATED DISEASE OR DISORDER
US12628858B2 (en) 2019-03-21 2026-05-19 Cornell University Therapy for colorectal and small intestine cancers
EP3963599B1 (en) 2019-04-30 2026-06-03 University of Southern California Fasting-mimicking diet (fmd) as an intervention for alzheimer's disease (ad)
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
JP2023529504A (ja) * 2020-06-14 2023-07-10 エル－ニュートラ・インコーポレイテッド ファスティング状態を維持及び延長する断続的なファスティングバー／ドリンク
WO2022008943A1 (ru) * 2020-07-10 2022-01-13 Елена Анатольевна МАРТЫНОВА Способ проведения курса голодания для тяжелобольных пациентов

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050302A2 (en) * 2009-10-22 2011-04-28 University Of Southern California Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
AU2011339929B2 (en) * 2010-12-06 2017-05-11 Tom C. Tsang Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
CA2900782C (en) * 2013-02-12 2022-09-27 University Of Southern California Methods and diets to protect against chemotoxicity and age related illnesses
RU2727960C2 (ru) * 2013-07-01 2020-07-28 Юниверсити Оф Саутерн Калифорния Состояние воздержания от пищи в качестве диетического лечения диабета
CN106456631A (zh) * 2014-03-06 2017-02-22 南加利福尼亚大学 利用短期饥饿方案结合激酶抑制剂来增强传统化学药物功效和可行性并逆转激酶在正常细胞和组织中的副作用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ERIC C. WOOLF ET AL, "The ketogenic diet for the treatment of malignant glioma", JOURNAL OF LIPID RESEARCH, US, (2014-02-06), vol. 56, no. 1, doi:10.1194/jlr.R046797, ISSN 0022-2275, pages 5 - 10 *

Also Published As

Publication number Publication date
RU2017136423A3 (cg-RX-API-DMAC10.html) 2019-09-04
CN107613979A (zh) 2018-01-19
EP4299061A2 (en) 2024-01-03
US20210137856A1 (en) 2021-05-13
RU2734774C2 (ru) 2020-10-23
EP4299061A3 (en) 2024-02-28
JP2021008491A (ja) 2021-01-28
IL255026A0 (en) 2017-12-31
ZA201707710B (en) 2019-04-24
EP3283073A2 (en) 2018-02-21
BR112017022244A2 (pt) 2018-07-10
JP2018511625A (ja) 2018-04-26
HK1249858A1 (zh) 2018-11-16
KR20180002677A (ko) 2018-01-08
CA2982875A1 (en) 2016-10-20
AU2016248443A1 (en) 2017-11-02
EP3283073A4 (en) 2019-02-13
WO2016168802A2 (en) 2016-10-20
CA3108664A1 (en) 2016-10-20
CA2982875C (en) 2021-10-19
RU2017136423A (ru) 2019-05-16
US20160303056A1 (en) 2016-10-20
MX2017013133A (es) 2018-09-07

Similar Documents

Publication Publication Date Title
ZA201707710B (en) Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
EP3297037A4 (en) Preparation method for solar cell piece unit and solar cell module
EP3084830A4 (en) Liner for phase change memory (pcm) array and associated techniques and configurations
EP3238070A4 (en) Memory protection with non-readable pages
EP3019936A4 (en) Fast multi-touch post processing
EP3227932A4 (en) Barrier film techniques and configurations for phase-change memory elements
EP3088951A4 (en) Array substrate, preparation method thereof, motherboard comprising array substrate and display apparatus
EP3069171A4 (en) Seismic data processing
EP3149607A4 (en) Fast access rights checking of configured structure data
EP3259868A4 (en) Protecting sensitive data security
EP3014670A4 (en) Transparent conductive coatings for organic photovoltaic films
EP3135678A4 (en) Heterocyclic compound and organic solar cell comprising same
EP3198466A4 (en) Multicore memory data recorder for kernel module
EP3041476A4 (en) Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
EP3298918A4 (en) Improvements to skull protection cell
EP3260456A4 (en) Heterocyclic compound and organic solar cell comprising same
EP3066496B8 (en) Device and method for detecting neutrons and gamma rays
EP3241116A4 (en) Memory access protection using processor transactional memory support
EP3287452A4 (en) Heterocyclic compound and organic solar cell comprising same
EP3058595A4 (en) Photovoltaic cells including halide materials
EP3140673A4 (en) Gamma detector protection for downhole operations
EP3276695A4 (en) Organic thin film solar cell module
EP3271828A4 (en) Cache and data organization for memory protection
EP3389098A4 (en) Solar cell module
EP3031449A4 (en) Entecavir microspheres and pharmaceutical composition for parenteral administration containing same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)